Objective: This study describes the incidence, correlates and subsequent morbidities of hyperglycemia, a highly prevalent condition in extremely low birth weight (ELBW) infants.
Introduction
Extremely low birth weight (ELBW) infants (birth weight (BW) <1000 g) have become the largest clinical population in the neonatal intensive care unit as a result of improved clinical care and enhanced survival. [1] [2] [3] Many of these infants have glucose intolerance resulting in hyperglycemia, a condition that has become increasingly important with reports of up to 68% of ELBW infants during the first few weeks of life. 4 In fact, the neonate with BW less than 1100 g is 18 times more likely to develop hyperglycemia than one who weighs more than 2000 g. 5 Several conditions have been implicated in the development of neonatal hyperglycemia, including intravenous fluids, parenteral nutrition, stress and drug treatment, in particular steroids. [6] [7] [8] [9] [10] Some investigators have evaluated the short-term adverse effects of hyperglycemia in the neonate; 1, 11 however, few have focused on long-term outcomes such as intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP) and death. 9, 10, 12 The majority of previous studies were performed when the survival of ELBW infants was significantly lower. Furthermore, no study has investigated the role of Hispanic ethnicity in the development of hyperglycemia in the premature infant. Thus, the aim of this study was to evaluate the incidence of hyperglycemia in ELBW infants in a predominantly Hispanic population, correlates and subsequent morbidities associated with this condition.
Materials and methods

Study population
A retrospective chart review of live-born infants with BW less than 1000 g admitted to University Hospital, San Antonio, TX, from January 1998 to December 2001, was conducted. All data were obtained by reviewing existing patient records. A total of 230 charts were reviewed. Pre-viable infants were excluded (45 infants); they were defined as infants who received no resuscitative measures due to extreme prematurity and survival was limited to a few hours with no interventions provided. Of the remaining 185 eligible patients, 16 were excluded due to incomplete medical records; the majority was of patients transferred into our facility after the study time period (first 2 weeks of life). w 2 analyses indicated that ineligible subjects exhibited comparable distribution of demographic and clinical characteristics relative to those included in the study sample. All infants were followed until death (if occurring in hospital), or until hospital discharge.
Data collection
Clinical and demographic data extracted from medical chart included gestational age (GA), BW, anthropometric data, gender, ethnicity, length of stay and death. GA was determined by the attending neonatologist based on clinical data along with maternal dates and/or prenatal ultrasound when available. GA data were dichotomized with an assigned value of 0 if GA was <26 weeks gestation, and a value of 1 if X26 weeks; BW was dichotomized with the following values: 0 if <750 g, and 1 if X750 g. Ethnicity was defined by mothers' self-designation at the time of admission; if that data were not available, then designation was assigned by maternal Spanish surname. Prenatal data collected included mode of delivery, antenatal corticosteroid use and chorioamnionitis as defined by the clinical assessment of the obstetrician and/or placental pathology report. The following data were recorded if present within the first 15 days of life: sepsis as defined by at least one positive blood, urine or cerebrospinal fluid culture; any major surgical intervention; and the use of corticosteroids, insulin and catecholamines with regard to the day of initiation, the number of days used and the dose.
Hyperglycemia was defined as a plasma glucose concentration of X150 mg/dl (8.3 mmol/l) on at least two different occasions during the first 15 days of life; this level has been previously identified as being clinically relevant. 4, 9, 13 Measurements of glucose levels were performed using the glucose oxidation technique (AU 640 Immuno Analyzer, Olympus Inc., Center Valley, PA, USA) at a frequency determined by the clinical status of each infant. The highest glucose value per day was recorded in all infants (G peak ). If the glucose value was X150 mg/dl, the number of days with hyperglycemia was recorded.
Glucose, protein and lipid infusion rates were generated from parenteral nutrition information sheets; the number of days to reach maximum lipid and protein infusion concentrations were recorded when information was available (95 charts). For each patient, the following nutritional variables were obtained: discharge anthropometrics, weight gain by 28 days of age (g/day), the day enteral feeds were initiated, the number of days required to reach full volume feeds and volume of enteral feeds on the day of G peak .
Outcomes reviewed included: bronchopulmonary dysplasia (BPD), defined as the need for oxygen at 36 weeks corrected GA; IVH noting the highest degree during hospitalization; and ROP, recording the most severe ROP examination staged by an ophthalmologist according to the International Classification of ROP.
14 The University of Texas Health Science Center San Antonio Institutional Review Board approved this study.
Statistical methods
All statistical analyses were performed with the Statistical Analysis System version 9.1. (SAS Institute, Cary, NC). Distributions and means of demographic and clinical variables were compared across study subgroups using w 2 tests and t-tests, respectively. Standard deviations are shown for continuous variables. Logistic regression was employed to assess correlates of hyperglycemia, and to assess the association of hyperglycemia with several clinical outcomes, after adjusting for GA, BW and postnatal steroid use. Owing to limited statistical power, only covariates of primary conceptual interest were included in the final multivariate analysis. Fisher's exact test was utilized when indicated.
Results
One hundred and fifty (88%) of the 169 patients included in this study developed hyperglycemia. Hispanics accounted for 71% of the total population, and males for 55%. No differences in gender and ethnicity were found between hyperglycemic and euglycemic infants. Being small for GA (SGA) at birth was not associated with hyperglycemia, although there were no SGA infants in the euglycemic group. The demographic details are summarized in Table 1 .
Infants with GA X26 weeks and BW X750 g were less likely to have hyperglycemia according to bivariate analysis, but only GA continued to reach statistical significance (odds ratio 0.11 ; 95% confidence interval 0.01-0.89) after adjusting for other study covariates (Table 2) . Infants born to a mother with chorioamnionitis were less likely to develop hyperglycemia, whereas sepsis and exposure to postnatal steroids were not associated with hyperglycemia (Table 2 ). Forty-four (26%) of the patients were exposed to postnatal steroids, dexamethasone accounting for 77% of the cases and hydrocortisone for the remainder.
Glucose levels
The mean plasma glucose level for the hyperglycemic group was 248±83 and 128±16 mg/dl for the euglycemic group. On average, hyperglycemic infants reached a G peak on day of life 6 (range 1-15 days), and remained hyperglycemic for 3.7 days (1-15 days). Iatrogenic hyperglycemia was found in 36 (21%) hyperglycemic infants who had a mean G peak of 194 mg/dl. This type of hyperglycemia resolved within 1 day; the glucose infusion rate (GIR) was significantly higher than the other hyperglycemic infants (8.0 vs 6.1 mg/kg/min, respectively, P ¼ 0.01).
Insulin was utilized in 14% of the infants with hyperglycemia. The criterion for insulin therapy was determined by the attending neonatologist. In general, this group of infants was younger by GA (insulin group 24.4±1.1 weeks, non-insulin group 26.0±2.2 weeks, P ¼ 0.002), remained hyperglycemic for a longer period of time (insulin group 5.2 days, non-insulin group 3.5 days, P ¼ 0.01) and had high mortality rate (90%). Catecholamine use (dopamine, dobutamine and epinephrine) was not associated with hyperglycemia (Table 1) .
Nutritional data
No significant difference was found in the volume of enteral feeds during G peak , initiation of enteral feeds, number of days to reach full feeds, GIR during G peak (Table 1) or days to reach maximum parenteral protein and lipid infusion rates between groups. The median number of days to reach maximum parenteral protein and lipid infusion in our cohort was 5 and 6.5 days, respectively. During the study period, the usual practice for advancing parenteral protein supplementation was to initiate 0.5 g/kg/day on the first day of life, and then advance by 0.5 g/kg every day to a maximum of 3 g/kg/day. Discharge anthropometric parameters and weight gain by 28 days of life were similar in both groups (data not shown).
Clinical outcomes BPD was diagnosed in 29%, ROP (any stage) in 59% and IVH was present in 24% of the population studied. Hyperglycemia was associated with a 4.5-fold increase in ROP even after correction for GA, BW and postnatal steroid use (Table 3) . Threshold ROP did not reach statistical significance, although laser treatment was required in 15 of 66 patients with ROP in the hyperglycemic group and in none of the three patients with ROP in the euglycemic group (P ¼ 0.21).
Hyperglycemia was not found to be associated with death, prolonged length of hospital stay (>than 90 days) or incidence of BPD or IVH (Table 3) .
Discussion
Despite the high prevalence of hyperglycemia in ELBW infants, little is known about factors associated with this condition and the impact on subsequent morbidities. 12, 15, 16 Although there are known complications of high glucose levels in conditions such as diabetes mellitus, the significance of hyperglycemia in ELBW infants is questionable. Most studies to date have linked hyperglycemia with short-term outcomes such as sepsis, glucosuria, osmotic diuresis and dehydration. 1, 3, 4, 9 Therefore, the aim of this study was to evaluate the incidence of hyperglycemia in ELBW infants, correlates and associated morbidities.
In our predominantly Hispanic population, the overall incidence of hyperglycemia during the first 2 weeks of life was 88%. Although higher than previously reported, other factors besides Hispanic ethnicity may lead to the development of this condition. Extreme prematurity as evidenced by lower GA, not BW, was the most important factor for the development of hyperglycemia. This supports the existing data that suggest hepatic glucose production, pancreatic beta cell response and insulin sensitivity are physiologically related and developmentally regulated. 3, [17] [18] [19] Contrary to previous reports, sepsis and postnatal steroid exposure during the first 2 weeks of life were not associated with hyperglycemia, although a trend existed with postnatal steroid exposure. The lack of association with steroids may be due to the small number of euglycemic patients or to the change in clinical practice of using lower dexamethasone doses and shorter regimens. Furthermore, the time of occurrence of both postnatal steroid exposure and diagnosis of sepsis did not occur prior to the development of hyperglycemia in many of the cases and were often coincidental, thus perpetuating glucose intolerance in infants already at high risk. Unfortunately, we were unable to sort out the time of occurrence due to overlapping of variables and the retrospective nature of the study. The protective nature of chorioamnionitis with hyperglycemia was a surprising finding that has never been reported; the nature of this association remains unclear and will need to be studied prospectively with pre-defined criteria for the diagnosis.
The infants with hyperglycemia had a 4.5-fold increase in ROP; this association has been reported in a single study. 12 Whether the increase in ROP is secondary to hyperglycemia or is just an expression of severity of illness is unknown. This study was not designed to answer that question, although no differences in other variables that express severity of illness such as BPD, IVH, death and prolonged length of stay were found. No association was found between hyperglycemia and threshold ROP, although the sample size does not allow for any conclusions here.
Many factors are involved in the development and progression of ROP. 20 Animal and human studies support the relationship between hyperglycemia and circulatory retinal changes, which, in conjunction with hypoxemia, can accelerate the onset and progression of diabetic retinopathy. [21] [22] [23] [24] Furthermore, it is well established that the prevention of proliferative retinopathy in diabetic adults requires the tightest possible glucose control. 22, 25 A number of study limitations need to be addressed. A retrospective design can demonstrate associations between variables but not causation. There was no control for the variation of parenteral glucose infusion, glucose monitoring and treatment among physicians. Our incidence of hyperglycemia might be higher due to intensive glucose monitoring and/or overly aggressive advancement of parenteral nutrition, as higher GIRs were observed on the infants classified as having iatrogenic hyperglycemia. Owing to the high incidence of hyperglycemia found in our population, the number of patients in the euglycemic group was lower than expected. Therefore, only covariates of primary conceptual interest were used in the multivariate analysis.
Understanding the metabolic complications associated with ELBW infants is important due to the increased survival of these infants and their extensive morbidities. Of particular interest is the growing concern of cell programming during critical periods of development. In particular, we do not understand the programming of glucose regulation and how the pancreas functions during this critical stage of extra uterine development for extremely premature infants and the subsequent development of disease later in life. 16, [26] [27] [28] Recent reports have shown that strict normalization of blood glucose levels among critically ill adults, most of them without a history of diabetes, achieved significant reductions in morbidity and mortality. Hence, it is important to elucidate if optimal glucose management may have an impact in the outcomes of these vulnerable infants. 29 In fact, current changes in clinical practice may have an impact on glucose control. An area of increasing interest is the early institution of parenteral amino-acid solutions in premature infants, which has shown to reduce hyperglycemia. 30 Therefore, future studies of glucose metabolism in ELBW infants are warranted.
Conclusion
The present study identifies lower GA as the main factor associated with hyperglycemia in ELBW infants during the first 2 weeks of life. Other factors such as chorioamnionitis need further investigation to elucidate their relationship to glucose metabolism. Hyperglycemia during the first weeks of life may be associated with an increased incidence of ROP.
As new evidence relating to the adverse effects of hyperglycemia in ELBW infants arises, well-constructed, prospective studies must be performed to investigate the short-and long-term benefits of tighter glucose control.
